Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies

Trial Profile

A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Carcinoma; Cervical cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Dec 2018 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
    • 31 Aug 2018 Biomarkers information updated
    • 27 Jul 2018 Planned End Date changed from 31 Dec 2017 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top